#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cardiac arrest Frontotemporal dementia Anaemia Rhabdomyosarcoma Glomerulonephritis acute Haemolytic uraemic syndrome Adenoid cystic carcinoma Osteogenesis imperfecta Paget's disease of the vulva Diffuse large B-cell lymphoma refractory Antiphospholipid syndrome Congenital leptin deficiency Stiff person syndrome Uterine leiomyosarcoma Lung adenocarcinoma More trials…

    Learn about Rare Diseases

    Extranodal marginal zone B-cell lymphoma (MALT type) Hereditary ataxia – Treatment Noonan syndrome – Trials in Disease Fabry’s disease – Life with Disease Metachromatic leukodystrophy – Basic Information Chordoma – Diagnostics CADASIL Hyperoxaluria – Treatment Adrenocortical carcinoma – Life with Disease Acute respiratory distress syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Levocetirizine Dihydrochloride Propranolol Durvalumab Toripalimab Altizide Fluocinolone Acetonide Trometamol Thiamine Nitrate Bromhexine Hydrochloride Emiplacel VRDN-003 Risperidone [18F]Fluoro-Peg-Folate Ranitidine Hydrochloride Dulaglutide Ly3556050 Mosliciguat O15-Water Nystatin Domperidone More therapies…

    Learn about Your Condition

    Ebola disease Rosai-Dorfman syndrome Ankylosing spondylitis Arteriosclerosis Wolfram syndrome Haemorrhage intracranial Pulmonary alveolar haemorrhage Erosive oesophagitis Caesarean section Monogenic diabetes Invasive breast carcinoma Abdominal infection Porphyria non-acute Psoriasis Ovarian epithelial cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Orszagos Onkologiai Intezet

Orszagos Onkologiai Intezet

Rath Gyorgy Utca 7-9, Kerulet, Budapest, 1122, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Adagrasib
    • Carboplatin
    • Cisplatin
    France Greece Hungary Italy Poland Spain

  • Study on the Safety and Effects of Favezelimab and Pembrolizumab for Patients with Blood Cancers

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Haematological malignancy
    Investigated Drugs:
    • Favezelimab
    • Pembrolizumab
    Germany Greece Hungary Italy

  • Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Clear cell renal cell carcinoma
    Investigated Drugs:
    • Belzutifan
    • Pembrolizumab
    Bulgaria Czechia Finland France Germany Greece +8

  • Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Doxorubicin
    • Paclitaxel
    • Pembrolizumab
    Belgium France Germany Hungary Ireland Poland +2

  • Study on the Safety and Effectiveness of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-Hodgkin’s lymphoma
    Investigated Drugs:
    • Lenalidomide
    • Tafasitamab
    Bulgaria Croatia Czechia Denmark Finland Hungary +4

  • Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Triptorelin
    • Giredestrant
    • Anastrozole
    France Germany Hungary Ireland Italy Spain +1

  • Study Comparing Tisotumab Vedotin with Chemotherapy for Patients with Recurrent or Metastatic Cervical Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Cervix carcinoma
    Investigated Drugs:
    • Dextran 70
    • Tisotumab Vedotin
    • Hypromellose
    Austria Belgium Czechia Finland France Germany +7

  • Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Newly Diagnosed Limited-Stage Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Small cell lung cancer limited stage
    Investigated Drugs:
    • Olaparib
    • Carboplatin
    • Cisplatin
    Belgium Bulgaria Estonia France Greece Hungary +5

  • Study Comparing Pembrolizumab and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Docetaxel
    Belgium Czechia Denmark Finland Germany Hungary +7

  • Study of Pembrolizumab and Axitinib Combination Versus Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Pembrolizumab
    • Sunitinib
    Czechia France Germany Hungary Ireland Poland +1
Previous Page
1 … 13 14 15 16 17
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!